Physician profile
Georges E Chahoud
NPI 1942390414
$936,704.44
in general payments reported to CMS, 2019-2025
35 companies · $148K in 2025
The $148K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110K · 2020: $29K · 2021: $65K · 2022: $132K · 2023: $247K · 2024: $206K · 2025: $148K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $301K · Honoraria: $129K · Travel and Lodging: $73K · Consulting Fee: $69K · Food and Beverage: $25K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,150 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300,633.50 |
| Honoraria | $129,492.50 |
| Travel and Lodging | $73,453.08 |
| Consulting Fee | $68,963.75 |
| Food and Beverage | $25,430.72 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,150.00 |
| Education | $150.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $187,551.63 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $168,090.99 | 2022-2024 | Verquvo |
| Abiomed | $166,104.39 | 2019-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $89,171.63 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $81,327.91 | 2020-2025 | Farxiga, Brilinta, Lokelma |
| Scpharmaceuticals INC. | $71,747.84 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56,558.66 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $30,852.86 | 2025 | |
| Cvrx, INC. | $26,023.01 | 2021-2025 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $21,329.21 | 2024 | Inpefa |
| Abbott Laboratories | $15,109.56 | 2019-2025 | Mitraclip, Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Lilly USA, LLC | $6,895.92 | 2023-2025 | Jardiance |
| Vifor Pharma, INC. | $5,201.25 | 2021-2023 | Veltassa |
| Edwards Lifesciences Corporation | $3,406.81 | 2019-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Impulse Dynamics (USA) INC. | $2,662.48 | 2022-2025 | Optimizer, Optimizer |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $1,200.00 | 2019 | |
| Medtronic, INC. | $1,191.12 | 2021-2025 | Corevalve Evolut R, Symplicity G3 |
| Qorumpartners | $372.87 | 2022 | |
| Medtronic Vascular, INC. | $332.22 | 2019-2020 | |
| Novo Nordisk INC | $242.08 | 2024 | Ozempic, Wegovy |
| Amgen INC. | $153.34 | 2019-2024 | Repatha |
| Globus Medical, INC. | $132.06 | 2025 | Senza |
| Kiniksa Pharmaceuticals, Ltd. | $130.21 | 2023 | Arcalyst |
| Daiichi Sankyo INC. | $125.00 | 2023 | Injectafer |
| Nevro Corp. | $123.07 | 2022 | |
| Itamar Medical INC | $122.83 | 2023 | Watchpatone |
| Abbvie INC. | $100.00 | 2021 | |
| Genzyme Corporation | $99.55 | 2022 | |
| Endotronix, INC. | $97.41 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| American Regent | $75.31 | 2024 | Injectafer |
| Kci USA, INC. | $66.08 | 2019 | |
| Penumbra, INC. | $45.42 | 2022 | |
| Pfizer INC. | $22.71 | 2025 | |
| Inspire Medical Systems, INC. | $21.11 | 2023 | Inspire |
| Livanova USA, INC. | $17.90 | 2023 | Lifesparc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Georges Chahoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.